JANX

Janux TherapeuticsD

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-20

View Chart

Current thesis

Composite grade D from latest DB weights. Momentum 41.1 / Value 41.1

Posture

Defensive

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta +0.0.

What can break

Mixed signals. Wait for cleaner trend confirmation.

Momentum

Value

Sentiment

N/A

Setup hits (3d)

0 · Net Neutral

AI TargetsBase - · Bull - · Bear -

Data freshness

Prices

As of 2026-07-20

Fundamentals

As of 2026-07-21 • Vendor: Data Vendor v1

Scores

As of 2026-07-20 • Model: HYBRID_IC_RP

AI Memo

Unavailable: No memo yet

Investment thesis

As of 2026-07-20

Supporting evidence

What

Grade D · Defensive

Confidence Medium · Net Neutral

Target $33.56

Why

Momentum41 · Δ7d +28.8

Value41 · Δ7d +0.0

SentimentN/A · Δ7d -

So what

Weak posture (Net Neutral). Prioritize risk control and patience.

Lead driver: Value · See fundamentals

Momentum

40% active weight

Current posture

7d trendImproving

Δ7d

+28.8

Δ21d

+41.9

Value

60% active weight

Current posture

7d trendFlat

Δ7d

+0.0

Δ21d

-17.8

Sentiment

N/A

Coverage pending

No current score

7d trendTrend unavailable

Trend unavailable

Δ7d

Δ21d

Why this grade

Composite grade D. Momentum 41.1 / Value 41.1

Fundamentals (TTM)

As of 2026-07-21

Market Cap

$991.61M

Beta

2.88

Shares Out

60.98M

P/E (TTM) · Derived

-8.9

P/S (TTM)

82.70

P/FCF (TTM) · Derived

-12.87

Rev YoY

+2177.9%

EPS YoY

+2.2%

Gross Margin

+85.6%

Op Margin

-1442.9%

Net Debt

-$944.43M

Current Ratio

17.01

As of 2026-07-20 • Updated nightlySource: Internal modelMethodology